M&A Deal Summary

Corza Health Acquires TachoSil

On September 16, 2020, Corza Health acquired medical products company TachoSil from Takeda for 564M USD

Acquisition Highlights
  • This is Corza Health’s 1st transaction in the Medical Products sector.
  • This is Corza Health’s largest (disclosed) transaction.
  • This is Corza Health’s 1st transaction in Japan.

M&A Deal Summary
Date 2020-09-16
Target TachoSil
Sector Medical Products
Buyer(s) Corza Health
Sellers(s) Takeda
Deal Type Divestiture
Deal Value 564M USD

Target

TachoSil

Osaka, Japan
TachoSil provides surgical patches used for bleeding control.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Corza Health

San Diego, California, United States
Category Company
Founded 2019
Sector Healthcare Services
DESCRIPTION

Corza Health makes investments in healthcare companies to help accelerate growth. Corza Health invest into high-caliber teams and provides appropriate relationships, learnings and support to create industry-leading brands, products and services. Corza Health was founded in 2019 and is based in San Diego, California.

DEAL STATS #
Overall 1 of 4
Sector (Medical Products) 1 of 4
Type (Divestiture) 1 of 1
Country (Japan) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-01 Surgical Specialties

Westwood, Massachusetts, United States

Surgical Specialties is a medical device company that develops and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions, and acute injury.

Buy -

Seller(S) 1

SELLER

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 5 of 6
Sector (Medical Products) 3 of 3
Type (Divestiture) 5 of 6
Country (Japan) 4 of 5
Year (2020) 2 of 3
Size (of disclosed) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-14 Takeda Pharmaceutical - Buccolam

Osaka, Japan

Takeda Pharmaceutical Co. Ltd. - Buccolam is the only buccal midazolam approved across Europe. This value-added product is indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures (PACS), the most common neurological emergency in children with an incidence of 18 to 23 cases per 100,000 per year.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-30 Takeda Pharmaceutical - Primary Care Product Assets

Osaka, Japan

Takeda Pharmaceutical Co. Ltd. - Primary Care 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for the global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi.

Sell $278M
Mergr

Product

Company

Legal